Elite in Thyroid Eye Disease

Dr. Raymond S. Douglas

Ophthalmology
653 N Town Ctr Dr, Suite 512, 
Las Vegas, NV 
Accepting New Patients
Elite in Thyroid Eye Disease
653 N Town Ctr Dr, Suite 512, 
Las Vegas, NV 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raymond Douglas is an Ophthalmologist in Las Vegas, Nevada. Dr. Douglas is rated as an Elite provider by MediFind in the treatment of Thyroid Eye Disease. His top areas of expertise are Thyroid Eye Disease, Graves Disease, Eyelid Drooping, and Ptosis. Dr. Douglas is currently accepting new patients.

His clinical research consists of co-authoring 89 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 43 articles and participated in 4 clinical trials in the study of Thyroid Eye Disease.

Specialties
Ophthalmology
Licenses
Ophthalmology in CA
Hospital Affiliations
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

653 N Town Ctr Dr, Suite 512, Las Vegas, NV 89144
Other Locations
9675 Brighton Way, Suite 410, Beverly Hills, CA 90210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Other, Biological
Study Phase: Phase 3
A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease
A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug, Biological
Study Drug: TEPEZZA
Study Phase: Phase 4
Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease
Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Biological
Study Phase: Phase 3
View 3 Less Clinical Trials

89 Total Publications

The Use of Biologics for Thyroid Eye Disease.
The Use of Biologics for Thyroid Eye Disease.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: May 05, 2025
Similar Doctors
Experienced in Thyroid Eye Disease
Dr. Kevin C. Firl
Ophthalmology
Experienced in Thyroid Eye Disease
Dr. Kevin C. Firl
Ophthalmology

Meadows Healthcare LLC

2749 Sunridge Heights Pkwy, 
Henderson, NV 
 (17.5 miles away)
702-358-0472
Languages Spoken:
English
See accepted insurances

Kevin Firl is an Ophthalmologist in Henderson, Nevada. Dr. Firl is rated as an Advanced provider by MediFind in the treatment of Thyroid Eye Disease. His top areas of expertise are Strabismus, Amblyopia, Esotropia, and Cataract.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Douglas's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile